Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

被引：2
|
作者：
Danilov, Alexey V. [1 ]
Lam, Vi [2 ]
Bria, Thurlow [3 ]
Spurgeon, Stephen E. [3 ]
Park, Byung [3 ]
Orand, Kirsten [4 ]
Kittai, Adam S. [5 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] Ohio State Univ, Div Hematol, Columbus, OH USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146348
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2643
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
  • [2] SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)
    Kittai, Adam S.
    Best, Scott R.
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Rowland, Taylor Hashiguchi
    Persky, Daniel O.
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey
    BLOOD, 2019, 134
  • [3] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [4] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [5] Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia
    Lam, Vi
    Best, Scott
    Kittai, Adam
    Orand, Kirsten
    Spurgeon, Stephen E.
    Liu, Tingting
    Danilov, Alexey V.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (02) : 836 - 841
  • [6] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [7] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [8] Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
    Kittai, Adam S.
    Best, Scott
    Thurlow, Bria
    Lam, Vi
    Hashiguchi, Taylor
    Goodyear, Shaun
    Persky, Daniel O.
    Okada, Craig
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    HAEMATOLOGICA, 2021, 106 (07) : 2022 - 2025
  • [9] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Jurczak, Wojciech
    Elmusharaf, Nagah
    Fox, Christopher P.
    Townsend, William
    Paulovich, Amanda G.
    Sharma, Shringi
    Parr, Graeme
    Munugalavadla, Veerendra
    Krantz, Fanny
    Yang, Helen
    Dean, Emma
    Manwani, Richa
    Hillmen, Peter
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
12345